{"id":2266,"date":"2026-06-10T20:00:00","date_gmt":"2026-06-10T23:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2266"},"modified":"2026-06-10T20:00:00","modified_gmt":"2026-06-10T23:00:00","slug":"pgrss-clinica-medicina-cir-oncologica-colorretal-esquerdo-sigmoide-apr-tatme-lateral-cetuximab-ras-wt","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/pgrss-clinica-medicina-cir-oncologica-colorretal-esquerdo-sigmoide-apr-tatme-lateral-cetuximab-ras-wt\/","title":{"rendered":"PGRSS colorretal E: sigmoide, APR, TaTME, cet"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores de cl\u00ednicas de cirurgia oncol\u00f3gica colorretal esquerdo que reduzem PGRSS a descarte de bisturi e gaze<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 cl\u00ednicas de cir oncol\u00f3gica colorretal esquerdo<\/strong> + CRC esquerdo descendente+sigmoide+retossigmoide 65%<\/strong> + APR amputa\u00e7\u00e3o abdominoperineal Miles + TaTME Trans-Anal Total Mesorectal Excision<\/strong> + LPLND Lateral Pelvic Lymph Node Dissection asi\u00e1tico<\/strong> + cetuximab Erbitux EGFR RAS-WT mais responsivo lado esquerdo CALGB 80405<\/strong> + panitumumab Vectibix EGFR + bevacizumab Avastin VEGF + sotorasib KRAS-G12C + tucatinib HER2 + KEYNOTE-177 MSI-H + BEACON BRAF V600E<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (CRC esquerdo descendente+sigmoide+retossigmoide+adenoCa+GIST+linfoma) + Grupo A4 (linfa CME+TME+LPLND lateral p\u00e9lvico obturador+il\u00edaca interna externa) + Grupo C (Y-90 SIRT met\u00e1stase hep\u00e1tica + Iridium-192 brachy intracavit\u00e1rio retal raro + HIPEC peritoneal) + Grupo E (perfuro bi\u00f3psia colonoscopia + ESD endoscopic + ressectosc\u00f3pio Storz\/Wolf) + Lista C5 (FOLFOX+FOLFIRINOX+CAPOX+pembrolizumab Keytruda KEYNOTE-177 MSI-H 1L+nivolumab Opdivo+cetuximab Erbitux EGFR RAS-WT esquerdo CALGB 80405+panitumumab Vectibix+bevacizumab Avastin+sotorasib Lumakras+adagrasib Krazati KRAS-G12C+tucatinib Tukysa HER2+larotrectinib+entrectinib NTRK+selpercatinib RET+BEACON encorafenib Braftovi+cetuximab BRAF V600E+regorafenib Stivarga+TAS-102 Lonsurf+fruquintinib Fruzaqla VEGFR FRESCO-2). A consequ\u00eancia \u00e9 a pr\u00e1tica de cl\u00ednicas que otimizam apenas para gaze cir\u00fargica<\/strong> + ignoram especificidades oncol\u00f3gicas + lateralidade biol\u00f3gica<\/strong> + subdimensionam Lista C5 imuno+targeted<\/strong> + perdem rastreabilidade tumor colorretal esquerdo<\/strong>. A realidade \u00e9 exatamente o oposto. PGRSS colorretal esquerdo opera em 5 fluxos oncol\u00f3gicos<\/strong> \u2014 A1 (CRC esquerdo 65% + adenoCa + GIST + linfoma), A4 (CME+TME+LPLND lateral p\u00e9lvico+APR Miles+TaTME), C (Y-90 SIRT + Iridium-192 raro + HIPEC), E (colonoscopia + ESD + LEEP), Lista C5 (FOLFOX+cetuximab CALGB 80405 esquerdo+pembrolizumab MSI-H+sotorasib KRAS+BEACON BRAF+fruquintinib FRESCO-2).<\/p>\n

Para o gestor que opera ou planeja cl\u00ednica de cir oncol\u00f3gica colorretal esquerdo, \u00e9 fundamental dimensionar PGRSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos oncol\u00f3gicos colorretal esquerdo<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o PGRSS colorretal esquerdo tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
A1 CRC esq+sigmoide<\/td>\n5-13 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nDesc+sigmoide+retoss<\/td>\n<\/tr>\n
A4 CME+TME+LPLND+APR<\/td>\n4-12 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nTaTME+lateral+Miles<\/td>\n<\/tr>\n
C Y-90+HIPEC<\/td>\n0,8-2,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nSIRT+Sugarbaker<\/td>\n<\/tr>\n
E colonoscopia+ESD<\/td>\n0,5-1,5 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nOlympus+Erbe+IT-knife<\/td>\n<\/tr>\n
Lista C5 cetux+pembro<\/td>\n1,5-4,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nCALGB 80405 esquerdo<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 11,8-33,5 kg\/dia<\/strong> em cl\u00ednica cir oncol\u00f3gica colorretal esquerdo m\u00e9dia porte.<\/p>\n

A1 CRC esquerdo descendente + sigmoide + retossigmoide: o est\u00e1gio cir\u00fargico<\/h2>\n

A primeira camada do PGRSS colorretal esquerdo \u00e9 A1. Padr\u00e3o setorial inclui (a) CRC esquerdo 65% colon descendente+sigmoide+retossigmoide+reto alto\/m\u00e9dio\/baixo<\/strong> com diferen\u00e7as biol\u00f3gicas vs direito + RAS-WT predominante + APC muta\u00e7\u00e3o + TP53 + SMAD4 + responsivo cetuximab\/panitumumab; (b) adenoCa colorretal esquerdo histologia<\/strong> com tubular+viloso+tubuloviloso+mucinoso 5-10% + grade well\/moderate\/poor + LVI+PNI + RAS+BRAF+MSI status imperativo; (c) estadiamento TNM 8\u00aa<\/strong> Tis+T1-T4a\/T4b+N0-N3+M0\/M1+CEA+CA 19-9+RAS+BRAF+MSI+HER2+NTRK+RET+TMB+sidedness right-sided vs left-sided; (d) CALGB 80405 PRIME<\/strong> RAS-WT lateralidade left-sided cetuximab+chemo OS 36-39m vs bevacizumab+chemo OS 32-34m HR favor\u00e1vel + right-sided bev favorecido; (e) outros<\/strong> GIST KIT+PDGFRA + carcinoide retal + linfoma MALT + sarcoma + melanoma anal + CID C18-C20 + Lynch testing universal screening 2022.<\/p>\n

Cl\u00ednica com A1 CRC esquerdo madura garante margem R0<\/strong> + previne recidiva regional<\/strong> + otimiza estadiamento TNM+RAS+sidedness<\/strong>. Como discutimos no post sobre colorretal direito<\/a>, A1 colorretal \u00e9 base.<\/p>\n

A4 CME + TME + TaTME + LPLND + APR Miles: o est\u00e1gio cir\u00fargico<\/h2>\n

A segunda camada \u00e9 t\u00e9cnica. Padr\u00e3o setorial inclui (a) CME Complete Mesocolic Excision + TME Total Mesorectal Excision Heald 1982<\/strong> com plano embriol\u00f3gico mesoc\u00f3lon+mesorretal + sharp dissection + sp\u00e9cimen intacto + dissec\u00e7\u00e3o CRM Circumferential Resection Margin >1mm; (b) TaTME Trans-Anal Total Mesorectal Excision<\/strong> com Sylla+Lacy 2010 + GelPOINT Path Applied Medical + SILS port Medtronic + Endopath Xcel + AirSeal CO2 + retal baixo\/ultra-baixo dif\u00edcil acesso; (c) LPLND Lateral Pelvic Lymph Node Dissection<\/strong> com asi\u00e1tico Jap\u00e3o padr\u00e3o retal baixo + obturador + il\u00edaca interna externa primitiva + nerve-sparing + redu\u00e7\u00e3o recidiva lateral 30-50%; (d) APR Miles abdominoperineal resection<\/strong> com sigmoidectomia + retossigmoide + canal anal + esf\u00edncter + colostomia definitiva fim-terminal + reconstru\u00e7\u00e3o perineal VRAM rectus abdominis+gracilis flap; (e) abordagem cir\u00fargica<\/strong> com aberto+laparosc\u00f3pico+rob\u00f3tica Da Vinci Xi+RAMIE colorretal + ICG indocyanine green angiografia perfus\u00e3o anastomose Spy-Plus+SPY-PHI Stryker.<\/p>\n

Cl\u00ednica com A4 TME+TaTME+LPLND+APR madura escala R0 90+%<\/strong> + escala f\u00edstula anastom\u00f3tica 5-15%<\/strong> + previne recidiva lateral 30-50% LPLND<\/strong>. Conex\u00e3o com retal baixa<\/a>.<\/p>\n

Cetuximab CALGB 80405 + KEYNOTE-177 MSI-H + BEACON BRAF + sotorasib KRAS + fruquintinib FRESCO-2: o est\u00e1gio sist\u00eamico+targeted<\/h2>\n

A terceira camada \u00e9 sist\u00eamico+targeted. Padr\u00e3o setorial inclui (a) FOLFOX+FOLFIRINOX+CAPOX 1L<\/strong> com cetuximab Erbitux Merck KGaA EGFR RAS-WT esquerdo CALGB 80405+PRIME OS 36-39m + panitumumab Vectibix Amgen EGFR RAS-WT + bevacizumab Avastin Genentech VEGF right-sided + AVAGAST + ML18147; (b) KEYNOTE-177 MSI-H 1L<\/strong> pembrolizumab Keytruda Merck 200mg q3w PFS 16,5m vs 8,2m FOLFOX HR 0,60 + dMMR-MSI-H 5% colorretal metast\u00e1tico + nivolumab Opdivo CheckMate-8HW+ipilimumab Yervoy 1L MSI-H; (c) BEACON CRC encorafenib Braftovi+cetuximab BRAF V600E 2L<\/strong> Pierre Fabre\/Pfizer 300mg PO QD + cetuximab + binimetinib Mektovi opcional + OS 9,3m vs 5,9m irinotecan\/FOLFIRI + 8-12% colorretal BRAF-mutated; (d) KRAS-G12C 3L<\/strong> sotorasib Lumakras Amgen 960mg PO QD CodeBreaK 100\/300 + adagrasib Krazati Mirati 600mg PO BID KRYSTAL-10 + 3% colorretal KRAS-G12C + tucatinib Tukysa+trastuzumab MOUNTAINEER HER2+ 3L; (e) 3L+ refrat\u00e1rio<\/strong> regorafenib Stivarga Bayer 160mg PO QD CORRECT + TAS-102 trifluridine\/tipiracil Lonsurf Taiho RECOURSE + fruquintinib Fruzaqla Takeda\/HUTCHMED VEGFR1\/2\/3 5mg PO QD FRESCO-2 OS 7,4m vs 4,8m placebo HR 0,66 + larotrectinib Vitrakvi+entrectinib Rozlytrek NTRK + selpercatinib Retevmo RET + watch-and-wait W&W cCR Lista C5.<\/p>\n

Cl\u00ednica com cetuximab+pembro+BEACON+sotorasib+fruquintinib madura escala CALGB 80405 OS 36-39m left-sided RAS-WT<\/strong> + escala KEYNOTE-177 PFS 16,5m MSI-H<\/strong> + escala BEACON OS 9,3m BRAF V600E<\/strong> + escala fruquintinib FRESCO-2 OS 7,4m<\/strong>. Conex\u00e3o com Lista C5<\/a>.<\/p>\n

Tr\u00eas perfis de PGRSS por capacidade colorretal esquerdo<\/h2>\n

Cl\u00ednica colorretal s\u00f3 A1.<\/strong> 1 fluxo. Custo mensal R$ 9.000-26.000<\/strong> mas perda de A4+C+E+sist\u00eamico.<\/p>\n

Cl\u00ednica colorretal A1 + A4 + FOLFOX.<\/strong> 3 fluxos. Custo mensal R$ 22.000-54.000<\/strong>, captura cirurgia + sist\u00eamico padr\u00e3o.<\/p>\n

Cl\u00ednica colorretal 5 fluxos completos.<\/strong> A1+A4+C+E+sist\u00eamico + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 40.000-95.000<\/strong>, efic\u00e1cia 95%, ROI 800-2.500% via captura completa colorretal esquerdo + CALGB 80405 OS 36-39m + KEYNOTE-177 MSI-H + BEACON BRAF.<\/p>\n

Os tr\u00eas erros que aparecem em cir oncol\u00f3gica colorretal esquerdo<\/h2>\n

O primeiro \u00e9 a subdimensionamento Lista C5 imuno+targeted CRC<\/strong>. Sem segrega\u00e7\u00e3o FOLFOX+FOLFIRINOX+pembrolizumab+nivolumab+cetuximab+panitumumab+bevacizumab+sotorasib+adagrasib+tucatinib+larotrectinib+selpercatinib+encorafenib+binimetinib+regorafenib+TAS-102+fruquintinib + Lista C5 = n\u00e3o-conformidade ANVISA RDC 222 + risco contamina\u00e7\u00e3o cruzada + impacto financeiro.<\/p>\n

O segundo \u00e9 a mistura A1 CRC esquerdo + direito + retal<\/strong>. Confunde rastreabilidade lateralidade + impossibilita CALGB 80405 sidedness left RAS-WT cetux vs right bev + risco indica\u00e7\u00e3o inadequada + perda OS 36-39m left.<\/p>\n

O terceiro \u00e9 a falta de protocolo MSI\/MMR + RAS+BRAF + HER2 + NTRK testing universal<\/strong>. Sem Lynch testing universal screening + comprehensive biomarker panel + FoundationOne CDx+Guardant360 + tumor mutational burden = perda elegibilidade targeted+imuno + zero precision medicine.<\/p>\n

A regula\u00e7\u00e3o de PGRSS colorretal esquerdo no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com cir oncol\u00f3gica preservadora como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com PGRSS cl\u00ednicas especializadas<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A INCA C\u00e2ncer Colorretal<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o PGRSS colorretal esquerdo 5 fluxos oncol\u00f3gicos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a A1 CRC esquerdo 65% descendente+sigmoide+retossigmoide+reto+RAS-WT predominante+APC+TP53+SMAD4+CALGB 80405 PRIME left-sided cetuximab OS 36-39m+CID C18-C20+TNM 8\u00aa, A4 CME+TME Heald 1982+TaTME Sylla+Lacy 2010+GelPOINT Path Applied Medical+SILS port+LPLND Lateral Pelvic Lymph Node Dissection asi\u00e1tico+obturador+il\u00edaca interna externa+nerve-sparing+APR Miles+VRAM+gracilis flap+colostomia+laparosc\u00f3pico+rob\u00f3tica Da Vinci Xi+RAMIE+ICG Spy-Plus+SPY-PHI Stryker, C HIPEC Sugarbaker+PIPAC+Y-90 SIR-Spheres+TheraSphere EPOCH\/SIRFLOX+Iridium-192 raro+CNEN-NN-3.05, E colonoscopia Olympus EVIS X1+Pentax+ESD Olympus EndoCut+Erbe VIO 300D+IT-knife+Hook-knife+Dual-knife+LEEP, Lista C5 FOLFOX+FOLFIRINOX+CAPOX+pembrolizumab Keytruda KEYNOTE-177 MSI-H 1L PFS 16,5m+nivolumab Opdivo CheckMate-8HW+ipilimumab+cetuximab Erbitux Merck KGaA EGFR RAS-WT esquerdo CALGB 80405+panitumumab Vectibix Amgen+bevacizumab Avastin+sotorasib Lumakras Amgen CodeBreaK 100\/300+adagrasib Krazati Mirati KRYSTAL-10 KRAS-G12C+tucatinib Tukysa+trastuzumab MOUNTAINEER HER2+larotrectinib+entrectinib NTRK+selpercatinib RET+BEACON encorafenib Braftovi+cetuximab+binimetinib Mektovi BRAF V600E OS 9,3m+regorafenib Stivarga Bayer CORRECT+TAS-102 Lonsurf RECOURSE+fruquintinib Fruzaqla Takeda\/HUTCHMED VEGFR FRESCO-2 OS 7,4m+watch-and-wait IWWD.<\/p>\n","protected":false},"excerpt":{"rendered":"

PGRSS colorretal esquerdo: sigmoide + APR + TaTME + cetuximab. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2265,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[3102,2712,2773,3101],"class_list":["post-2266","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-cetuximab","tag-cirurgia-oncologica","tag-colorretal","tag-sigmoide"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2266"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2266\/revisions"}],"predecessor-version":[{"id":4356,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2266\/revisions\/4356"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2265"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2266"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2266"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}